Compare Gilead Sciences, Inc. (GILD) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Western Alliance Bancorporation — how do they compare? Gilead Sciences, Inc. trades at $146.99 (market cap $182.09B), while Western Alliance Bancorporation trades at $76.21 (market cap $8.11B). The key difference: Gilead Sciences, Inc. is far larger — about 22.5× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays the higher dividend (2.26%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Western Alliance Bancorporation for 3 Days on average.
| GILD | WAL | |
|---|---|---|
Market Cap | $182.09B | $8.11B |
Volume | 4,960,247 | 1,479,953 |
Sector | Health | Financials |
52-Week High | $155.80 | $96.08 |
52-Week Low | $116.74 | $66.70 |
Typical Hold Time | 111 Days | 3 Days |
Enterprise Value | $205.15B | $9.63B |
Dividend Yield | 2.23% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% on the day, with a bearish technical outlook despite strong fundamentals. The company maintains robust profitability with 25.43% net income margin and 13.43% ROE, supported by recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX digital asset platform and participation in major financial conferences, while institutional investors show mixed positioning.
WAL presents a compelling value opportunity with attractive valuation multiples (P/E 8.39, P/B 1.07) and strong analyst support (79% buy ratings, $84.33 consensus target). However, near-term risks include the recent Q2 2026 EPS miss, bearish technical indicators, and regulatory uncertainty around Fed policy changes affecting bank asset thresholds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
